A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

BACKGROUND: Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. METHODS: All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Infect Dis
Autors principals: Capetti, Amedeo F., Cossu, Maria Vittoria, Orofino, Giancarlo, Sterrantino, Gaetana, Cenderello, Giovanni, De Socio, Giuseppe V., Cattelan, Anna Maria, Soria, Alessandro, Rusconi, Stefano, Riccardi, Niccolò, Baldin, Gian Maria, Niero, Fosca P., Barbarini, Giorgio, Rizzardini, Giuliano
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622573/
https://ncbi.nlm.nih.gov/pubmed/28964268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-017-2755-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars